Medpace Holdings, Inc. filings document formal disclosures for a global clinical contract research organization, including 8-K reports that furnish quarterly and annual financial results. Those reports cover operating measures such as revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios for its Phase I-IV clinical development services.
Medpace filings also include proxy materials addressing governance, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document credit-facility amendments involving operating subsidiaries and executive-officer succession matters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.80%
Tags
-
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.80%
Tags
-
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.80%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
FAQ
How many Medpace Holdings (MEDP) SEC filings are available on StockTitan?
StockTitan tracks 128 SEC filings for Medpace Holdings (MEDP), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Medpace Holdings (MEDP)?
The most recent SEC filing for Medpace Holdings (MEDP) was filed on July 24, 2025.